CGON
insider transactionsCG Oncology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-31.7K
0 buy · 31.7K sell
Net value · 365d
-$2.0M
$0 in · $2.0M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
8
0 buy · 31.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Director · 10b5-1
$0
1.3K sh
Own +100%
-
Exercise·M
Director · 10b5-1
$0
654 sh
Own New
-
Sell·S
Director · 10b5-1
$78.8K
1.3K sh · $60.12
Own -100%
-
Exercise·M
Director · 10b5-1
$16.5K
1.3K sh · $12.59
Own New
-
Sell·S
Director · 10b5-1
$39.3K
654 sh · $60.12
Own -100%
-
Exercise·M
Director · 10b5-1
$2.4K
654 sh · $3.72
Own New
-
Grant·A
Director · 10b5-1
$0
9.4K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
1.0K sh
Own +1%
-
Sell·S
Director · 10b5-1
$54.5K
1.0K sh · $54.50
Own -100%
-
Exercise·M
Director · 10b5-1
$600
1.0K sh · $0.60
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Grant·A
Director
$0
9.4K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
15.6K sh
Own New
-
Sell·S
Director · 10b5-1
$1.1M
15.6K sh · $73.01
Own -100%
-
Exercise·M
Director · 10b5-1
$571.4K
15.6K sh · $36.63
Own New
-
Grant·A
Chief Medical Officer
$0
79.2K sh
Own New
-
Grant·A
General Counsel and Chief Com…
$0
45.3K sh
Own New
-
Grant·A
James M. Detore KEY
Chief Financial Officer
$0
90.6K sh
Own New
-
Grant·A
Arthur Kuan KEY
Chief Executive Officer
$0
271.6K sh
Own New
-
Grant·A
Ambaw Bellete KEY
President and COO
$0
107.5K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
1.3K sh
Own +50%
-
Exercise·M
Director · 10b5-1
$0
654 sh
Own New
-
Sell·S
Director · 10b5-1
$83.2K
1.3K sh · $63.50
Own -100%
-
Exercise·M
Director · 10b5-1
$16.5K
1.3K sh · $12.59
Own New
-
Sell·S
Director · 10b5-1
$41.5K
654 sh · $63.50
Own -100%
-
Exercise·M
Director · 10b5-1
$2.4K
654 sh · $3.72
Own New
-
Exercise·M
Arthur Kuan KEY
Chief Executive Officer
$0
64.6K sh
Own New
-
Other·F
Arthur Kuan KEY
Chief Executive Officer
$111.1K
1.8K sh · $60.15
Own -1%
-
Exercise·M
Arthur Kuan KEY
Chief Executive Officer
$111.1K
64.6K sh · $1.72
Own +47%
-
Exercise·M
Arthur Kuan KEY
Chief Executive Officer
$0
102.9K sh
Own New
-
Other·F
Arthur Kuan KEY
Chief Executive Officer
$176.9K
2.9K sh · $61.61
Own -2%
-
Exercise·M
Arthur Kuan KEY
Chief Executive Officer
$176.9K
102.9K sh · $1.72
Own +285%
-
Exercise·M
Director · 10b5-1
$0
10.5K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
654 sh
Own +100%
-
Sell·S
Director · 10b5-1
$555.9K
10.5K sh · $52.99
Own -100%
-
Exercise·M
Director · 10b5-1
$132.1K
10.5K sh · $12.59
Own New
-
Sell·S
Director · 10b5-1
$28.9K
654 sh · $44.16
Own -100%
-
Exercise·M
Director · 10b5-1
$2.4K
654 sh · $3.72
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | James Mulay 10b5-1 | Exercise M | 1.3K | $0 |
| Jun 15, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $0 |
| Jun 15, 2026 | James Mulay 10b5-1 | Sell S | 1.3K | $78.8K |
| Jun 15, 2026 | James Mulay 10b5-1 | Exercise M | 1.3K | $16.5K |
| Jun 15, 2026 | James Mulay 10b5-1 | Sell S | 654 | $39.3K |
| Jun 15, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $2.4K |
| Jun 4, 2026 | Leonard E Post 10b5-1 | Grant A | 9.4K | $0 |
| Jun 4, 2026 | Leonard E Post 10b5-1 | Exercise M | 1.0K | $0 |
| Jun 4, 2026 | Leonard E Post 10b5-1 | Sell S | 1.0K | $54.5K |
| Jun 4, 2026 | Leonard E Post 10b5-1 | Exercise M | 1.0K | $600 |
| Jun 4, 2026 | Brian Guan-Chyun Liu | Grant A | 9.4K | $0 |
| Jun 4, 2026 | Victor Edward Tong Jr | Grant A | 9.4K | $0 |
| Jun 4, 2026 | James Mulay | Grant A | 9.4K | $0 |
| Jun 4, 2026 | Christina Rossi | Grant A | 9.4K | $0 |
| Jun 4, 2026 | Susan E Graf | Grant A | 9.4K | $0 |
| Apr 17, 2026 | James Mulay 10b5-1 | Exercise M | 15.6K | $0 |
| Apr 17, 2026 | James Mulay 10b5-1 | Sell S | 15.6K | $1.1M |
| Apr 17, 2026 | James Mulay 10b5-1 | Exercise M | 15.6K | $571.4K |
| Apr 15, 2026 | Vijay Kasturi | Grant A | 79.2K | $0 |
| Apr 15, 2026 | Joshua F. Patterson | Grant A | 45.3K | $0 |
| Apr 15, 2026 | James M. Detore KEY | Grant A | 90.6K | $0 |
| Apr 15, 2026 | Arthur Kuan KEY | Grant A | 271.6K | $0 |
| Apr 15, 2026 | Ambaw Bellete KEY | Grant A | 107.5K | $0 |
| Mar 16, 2026 | James Mulay 10b5-1 | Exercise M | 1.3K | $0 |
| Mar 16, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $0 |
| Mar 16, 2026 | James Mulay 10b5-1 | Sell S | 1.3K | $83.2K |
| Mar 16, 2026 | James Mulay 10b5-1 | Exercise M | 1.3K | $16.5K |
| Mar 16, 2026 | James Mulay 10b5-1 | Sell S | 654 | $41.5K |
| Mar 16, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $2.4K |
| Mar 12, 2026 | Arthur Kuan KEY | Exercise M | 64.6K | $0 |
| Mar 12, 2026 | Arthur Kuan KEY | Other F | 1.8K | $111.1K |
| Mar 12, 2026 | Arthur Kuan KEY | Exercise M | 64.6K | $111.1K |
| Mar 4, 2026 | Arthur Kuan KEY | Exercise M | 102.9K | $0 |
| Mar 4, 2026 | Arthur Kuan KEY | Other F | 2.9K | $176.9K |
| Mar 4, 2026 | Arthur Kuan KEY | Exercise M | 102.9K | $176.9K |
| Jan 9, 2026 | James Mulay 10b5-1 | Exercise M | 10.5K | $0 |
| Jan 9, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $0 |
| Jan 9, 2026 | James Mulay 10b5-1 | Sell S | 10.5K | $555.9K |
| Jan 9, 2026 | James Mulay 10b5-1 | Exercise M | 10.5K | $132.1K |
| Jan 9, 2026 | James Mulay 10b5-1 | Sell S | 654 | $28.9K |
| Jan 9, 2026 | James Mulay 10b5-1 | Exercise M | 654 | $2.4K |
About CGON insider trading
This page tracks insider transactions for CG Oncology, Inc. (CGON) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.